TNF and rheumatoid arthritis: Adalimumab (Ada) is a fully humanized anti-TNF-α monoclonal antibody given by subcutaneous route fortnightly and has a less pronounced toxicity profile.115 Anti-Ada antibodies (AAA) are detected in more than half of the treated patients with RA.